BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal

The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets.

BeOne Medicines and Revolution Medicines have entered a multi-part oncology collaboration covering combination studies involving BeOne pipeline assets and four clinical-stage RAS(ON) inhibitors — daraxonrasib, zoldonrasib, elironrasib and RMC-5127 — alongside exclusive regional development and commercialisation rights in selected Asian markets.

The agreement combines BeOne’s development and regional commercial infrastructure with Revolution Medicines’ RAS-targeted portfolio and creates opportunities to evaluate new combination approaches for patients with RAS-addicted cancers.

Field	Content
Alert Type	Deal
Companies	BeOne Medicines; Revolution Medicines
Deal Type	Clinical development collaboration and regional licensing agreement
Asset or Company	Revolution Medicines’ daraxonrasib, zoldonrasib, elironrasib and RMC-5127; BeOne’s BGB-58067 and BG-T187 among the planned combination assets
Therapy Area(s)	Oncology; RAS-addicted cancers
Technology or Modality	RAS(ON) inhibitors; PRMT5 inhibitor; trispecific EGFR × MET × MET antibody
Deal Value	Financial terms were not fully disclosed. Revolution Medicines is eligible to receive development and sales milestone payments plus tiered royalties on net sales from the licensed Asian territories.
Development Stage	Clinical stage; the four Revolution Medicines RAS(ON) inhibitors are in clinical development, with BeOne also responsible for funding and conducting a global registrational Phase III trial for one of the assets.
Geography	Global clinical collaboration plus selected Asian markets for licensed rights. Revolution Medicines retains rights outside the licensed territories, including Japan and South Korea.
What Happened	On 11 August 2026, BeOne Medicines and Revolution Medicines announced a multi-part collaboration focused on RAS-addicted cancers. The companies plan to evaluate combinations of BeOne pipeline assets, including the MTA-cooperative PRMT5 inhibitor BGB-58067 and trispecific EGFR × MET × MET antibody BG-T187, with Revolution Medicines’ four clinical-stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib and RMC-5127. Separately, Revolution Medicines granted BeOne exclusive development and commercialisation, or commercialisation-only rights depending on the territory, for the four RAS(ON) inhibitors in selected Asian markets. BeOne will also fund and conduct a global registrational Phase III trial for one of the Revolution Medicines assets.
Why It Matters	The agreement extends the development opportunities for Revolution Medicines’ RAS(ON) portfolio beyond monotherapy by testing combinations with mechanistically different oncology assets from BeOne. It also gives BeOne access to four clinical-stage RAS-targeted programmes across selected Asian markets, allowing the company to use its development and commercial infrastructure to support their regional development and potential launches.
Supporting Context	RAS alterations are important oncogenic drivers across multiple tumour types and have historically been difficult to target therapeutically. Revolution Medicines is developing RAS(ON) inhibitors designed to target active RAS proteins, while BeOne has a broader oncology pipeline containing potential combination partners with different mechanisms of action.
Strategic Rationale	Revolution Medicines gains access to BeOne’s oncology assets for combination studies while retaining development and commercial rights to its RAS(ON) programmes outside the licensed Asian territories. BeOne gains regional rights to four clinical-stage RAS inhibitors and the opportunity to evaluate its existing oncology pipeline in combinations that could potentially broaden the therapeutic application of both companies’ programmes.
Potential Impact	Successful studies could establish additional combination strategies for RAS-addicted cancers and broaden the development opportunities for both companies’ oncology pipelines. Any clinical or commercial impact will depend on trial results and subsequent regulatory approvals.
Key Takeaway	The collaboration combines BeOne’s oncology pipeline and Asian development infrastructure with four Revolution Medicines RAS(ON) inhibitors, creating both new combination programmes and a regional commercial partnership.
What to Watch	Initiation and results of the planned combination studies, identification of the RAS(ON) inhibitor selected for BeOne’s global registrational Phase III trial and subsequent development and regulatory progress across the licensed Asian territories.
Primary Source	BeOne Medicines / Revolution Medicines collaboration announcement
Relevant Date	11 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com